BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jul 23, 2007
 |  BioCentury  |  Finance

EPS watch

EPS watch

EPS watch
Actelion and Cubist were the big winners last week, both gaining 13% after posting second quarter earnings. Gilead, despite reporting 48% EPS growth over the same period last year, was off 3% - about $1.1 billion. Investors may have been disappointed with sales of HIV drug Atripla, which came in at $212.4 million versus Street expectations of about $241 million based on an average of three analyst estimates. Also last week, the non-profit Public Patent Foundation announced that the U.S. Patent and Trademark Office granted its request to review four patents underlying GILD's HIV treatment Viread (see name Missing Atripla Play, A17). (A) Results for 1Q fiscal 08
Company 2Q07 EPS est 2Q07 EPS actual Outcome Growth from 2Q06 7/20 cls Wk chg % chg Mcap chg 7/20 Mcap
Abbott (ABT) $0.68 $0.69 Beat by $0.01 11% $52.87 -$0.37 -1% -$577.4 $82,512.5
U.S. pharmaceutical sales increased 27% to $1.9B. ABT narrowed its FY07 EPS guidance, excluding specified items, to $2.80-$2.84 from $2.79-$2.85 to reflect the retention of its core laboratory diagnostics business. ABT had expected...

Read the full 1005 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >